Goodsurance
ES

Drug prices & Part D

Federal Watchdog: Medicare Drug Plans Tied to Pharmacy Chains Offer Lower Premiums but Substantially Higher Drug Costs

With open enrollment eight days away, a federal audit found that Part D plans run by companies that also own pharmacies and pharmacy benefit managers dominate the market, but their enrollees pay substantially more out of pocket when filling prescriptions.

By the Goodsurance editorial teamOctober 7, 2026

A federal watchdog report published in May found that Medicare Part D drug plans operated by companies that also own pharmacy chains and pharmacy benefit managers have come to dominate the market, but those plans tend to leave enrollees paying substantially more out of pocket for their prescriptions than plans that do not have those ownership connections.

The Office of Inspector General examined the role of vertical integration in Part D, looking at companies where the insurer, the pharmacy benefit manager, and retail pharmacy operations all fall under common ownership. In 2023, just 6 of the 11 vertically integrated organizations the OIG identified accounted for about 82 percent of the 275.9 billion dollars in total Part D spending that year.

Lower premium, higher pharmacy bill: a federal report explains the Part D tradeoff that matters most before open enrollment closes December 7.

Those plans charged lower monthly premiums. But enrollees in vertically integrated plans paid substantially higher drug out-of-pocket costs compared with enrollees in other Part D plans, the OIG found. The gap was most pronounced for enrollees who did not qualify for Extra Help or other low-income subsidy programs. Those subsidy programs cap most prescription cost-sharing regardless of which plan a person chooses, so enrollees who receive them are largely shielded from the tradeoff.

The OIG noted that it could not fully measure all payment adjustments made after the point of sale, meaning the complete picture of how vertical integration affects net pharmacy costs remained unclear.

The finding arrives as Medicare's Annual Enrollment Period opens October 15 and runs through December 7. Beneficiaries can compare both monthly premiums and estimated out-of-pocket drug costs for their specific prescriptions at Medicare.gov using the Plan Finder tool, which draws on each plan's formulary and cost-sharing data.

In plain words

Some Medicare drug plans are owned by the same companies that run pharmacies and manage prescription benefits. A federal report found those plans usually charge a lower monthly fee. But the people in those plans often pay more when they actually pick up their medicine.

This matters most if you do not get Extra Help or another government program that caps what you pay for drugs. If you do get Extra Help, you are mostly protected no matter which plan you are in.

Open enrollment runs from October 15 to December 7. You can go to Medicare.gov and use Plan Finder to see what each plan would charge for your exact medicines. Looking at both the monthly fee and the pharmacy cost together gives you a better picture of what you would actually spend.

Source: OIG
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Medicare Insulin Costs Cut in Half Since 2020, KFF Report Finds

Per-prescription out-of-pocket insulin spending for Part D enrollees without low-income help fell from 54 dollars in 2020 to 25 dollars in 2024, driven by manufacturer pricing changes and a federal monthly cap that took effect in 2023.

November 21, 2026

Drug prices & Part D

Medicare Part D Rarely Covers the OTC Naloxone Nasal Spray. Medicaid Usually Does.

A new Government Accountability Office report finds that most Part D plans stopped covering the over-the-counter naloxone nasal spray after it no longer required a prescription, while Medicaid covers the same product at little or no cost to enrollees.

November 16, 2026

Drug prices & Part D

Biotech Industry Group Files Second Lawsuit to Block Medicare's GLOBE Drug Pricing Model

BIO and two California biotech groups sued CMS on November 6, arguing the program exceeds legal authority. A first challenge from PhRMA filed in October remains pending.

November 12, 2026

Drug prices & Part D

KFF: Medicare's 340B Drug Payment Cut Reduces Revenue for Safety-Net Hospitals While Raising It for For-Profit Ones

Now that the 2027 outpatient rule is final, a KFF analysis finds the 340B reimbursement cut falls hardest on hospitals that serve low-income patients, while for-profit hospitals see a net gain.

November 11, 2026

Drug prices & Part D

Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The CMS-4215-F final rule, published today, converts the negotiation program from administrative guidance into binding federal regulation for every drug-price cycle starting in 2029, and requires Part D plans to cover negotiated-price drugs on their formularies.

November 9, 2026

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026